Arena Airs More Mixed Data For Late-Stage Obesity Drug Lorcaserin

New Phase III data for Arena Pharmaceuticals' novel obesity compound lorcaserin have disappointed the market once again, even though the company is arguing that technically speaking, they will do the trick in satisfying guidelines for FDA approval

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet